Wanbury’s Patalganga manufacturing facility clear US FDA inspection with zero observations
Wanbury exports APIs to more than 70 countries including the US, Europe and Latin America
Pharma company Wanbury, having a presence in the API global market and domestic branded formulation announced the successful completion of the United States Food & Drug Administration (US FDA) inspection at the Patalganga site, Maharashtra. The inspection was concluded with zero-483 observations.
Mohan Rayana, Director, Wanbury said, “We are pleased to announce the successful completion of the US FDA inspection at our Patalganga site, resulting in zero Form 483 observations. This achievement underscores our commitment to the highest quality and compliance standards at both our API manufacturing sites in Patalganga, Maharashtra, and Tanuku, Andhra Pradesh, both of which are US FDA approved.”
Wanbury exports APIs to more than 70 countries including the US, Europe and Latin America.
Recommended
Biju Nair joins Care Hospitals as zonal COO in Hyderabad
November 4, 2024
Ramaiah Memorial Hospital launches Ramaiah Stroke Center
November 4, 2024
Herbalife India, IIT Madras launch 1,000 data science scholarships
November 4, 2024